Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11976297 Engineered immune cells with receptor cross-talk

Patent 11976297 was granted and assigned to A2 Biotherapeutics, Inc on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 11976297 Engineered immune cells with receptor cross-talk

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo